Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

NCT ID: NCT04984707

Last Updated: 2021-07-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-01-28
• Study Completion Date: 2019-10-24

Brief Summary

The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration

Detailed Description

A total of 40 subjects will be evaluated with 32 subjects randomized to receive active drug and 8 subjects randomized to receive placebo in a double-blind fashion (ten subjects in each dose cohort with two subjects randomized to placebo for total of four dose cohorts).Subjects were to be assigned to 1 of the 4 dose levels, 3 mg. 12 mg, 48 mg and 96 mg of KX-826 or placebo to match the active product, administered as a topical application.

Conditions

Androgenetic Alopecia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Experimental Group -KX0826

KX0826 is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.The applied dosage cohorts are 3mg, 12mg, 48mg and 96mg.

Group Type: EXPERIMENTAL

KX0826

Intervention Type: DRUG

AR antagonist

Control Group- Placebo

Placebo is tropically applied to the scalp of healthy male subjects with Androgenetic Alopecia with a single dose.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo of KX-826

Interventions

KX0826

AR antagonist

Intervention Type: DRUG

Placebo

Placebo of KX-826

Intervention Type: OTHER

Other Intervention Names

Pyrilutamide; KX-826

Eligibility Criteria

Inclusion Criteria

1. Are capable of giving informed consent and complying with study procedures;

2. Are males between the ages of 18 and 60 years, inclusive;

3. Have a clinical diagnosis of AGA;

4. Considered healthy by the PI, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs;

5. Have normal renal and hepatic function as determined by the screening laboratory results;

6. Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6 months before screening;

7. Body mass index (BMI) of 19.0 to 35.0 kg/m2 inclusive and body weight not less than 50 kg;

8. Willing and able to adhere to study restrictions and to be confined at the clinical research center.

Exclusion Criteria

1. Clinically significant history of gastrointestinal (GI), cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity;

2. Any visible skin disease, damage or condition at the application site which, in the opinion of the investigator, could compromise subject safety and/or interfere with the evaluation of the test site reaction;

3. Subject has any dermatological disorders of the scalp;

4. Subject has a history of hair transplants, hair weaves;

5. Subject has hypersensitivity to previously prescribed minoxidil or finasteride;

6. Known or suspected malignancy;

7. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBs Ag), or hepatitis C (HCV) antibody;

8. A hospital admission or major surgery within 30 days prior to screening;

9. Participation in any other investigational drug trial within 30 days prior to screening;

10. A history of prescription drug abuse, or illicit drug use within 6 months prior to screening;

11. A history of alcohol abuse according to medical history within 6 months prior to screening;

12. A positive screen for alcohol or drugs of abuse;

13. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening;

14. Use of prescription or over the counter (OTC) medications, and herbal (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at < 3g/day was permitted until 24 hours prior to dosing);

15. An unwillingness of male participants to use appropriate contraceptive measures if engaging in sexual intercourse with a female partner of childbearing potential. Appropriate measures include use of a condom and spermicide and, for female partners, use of an intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable progesterone, progesterone subdermal implants, or a tubal ligation.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David J Wyatt, MD

Role: PRINCIPAL_INVESTIGATOR

inVentiv Health Clinical Research Services,LLC

Locations

inVentiv Health Clinical Research Services LLC

Miami, Florida, United States

Countries

United States

Other Identifiers

KX0826-US-1001

Identifier Type: -

Identifier Source: org_study_id